Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) – Part II: In vivo Efficacy Testing in a Rabbit Surfactant Washout Model
The new dry powder aerosol SLS product (which includes the delivery strategy, formulation, and delivery system) has the potential to be a safe, effective, and economical alternative to the current clinical standard of liquid bolus surfactant instillation.
Authors
- Dale Farkas (ORCID: https://orcid.org/0000-0001-7295-7555)
- Michael Hindle (ORCID: https://orcid.org/0000-0002-1025-1183)
- P. Worth Longest (ORCID: https://orcid.org/0000-0003-4939-5691)
- Felicia Hall
- Mohammad A. M. Momin (ORCID: https://orcid.org/0000-0003-1463-0719)
- Robert M DiBlasi (ORCID: https://orcid.org/0000-0002-9206-7346)
- Niko Kontoudios (ORCID: https://orcid.org/0009-0006-5021-3858)
- Hattie KenKnight
Institutions
- Center for Infectious Disease Research (US)
- Virginia Commonwealth University (US)
- Seattle Children's Hospital (US)
Publication Details
- Journal
- Pharmaceutical Research
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1007/s11095-024-03754-7
- Citations
- 6
- Primary Topic
- Neonatal Respiratory Health Research
- Type
- article
- Field-Weighted Citation Impact
- 2.51
Funders
- Bill and Melinda Gates Foundation